Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017202786 - MATERIALS AND METHODS RELATING TO DOSAGE REGIMEN DESIGN

Publication Number WO/2017/202786
Publication Date 30.11.2017
International Application No. PCT/EP2017/062302
International Filing Date 22.05.2017
IPC
G06F 19/00 2011.01
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
FELECTRIC DIGITAL DATA PROCESSING
19Digital computing or data processing equipment or methods, specially adapted for specific applications
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07K 14/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
55IL-2
C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
G01N 33/557
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
557using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Applicants
  • F. HOFFMANN-LA ROCHE AG [CH]/[CH] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • HOFFMANN-LA ROCHE INC. [US]/[US] (US)
Inventors
  • GRIMM, Hans Peter
  • RIBBA, Benjamin
  • TEICHGRAEBER, Volker
Agents
  • CUENI, Leah
Priority Data
16171263.325.05.2016EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MATERIALS AND METHODS RELATING TO DOSAGE REGIMEN DESIGN
(FR) MATÉRIAUX ET PROCÉDÉS RELATIFS À LA CONCEPTION D’UNE POSOLOGIE
Abstract
(EN)
The present invention provides materials and methods for determining optimal dosage regimens for therapeutic agents. In particular, the invention relates to dosage regimens for therapeutic agents capable of targeting IL-2 receptor, preferably interleukin 2 (IL2)-based therapeutic agents. The methods of the invention allow general dosage regimens to be determined for new IL-2R targeted therapeutic agents but also specifically tailored dosage regimens to be achieved for individuals being treated with IL-2R targeted therapeutic agents.
(FR)
La présente invention concerne des matériaux et des procédés permettant de déterminer des posologies optimales pour des agents thérapeutiques. L’invention concerne en particulier des posologies pour des agents thérapeutiques capables de cibler le récepteur de l’IL-2, de préférence des agents thérapeutiques basés sur l’interleukine 2 (IL2). Les procédés de l’invention permettent de déterminer des posologies générales pour de nouveaux agents thérapeutiques ciblés sur l’IL-2R, mais permettent également de réaliser des posologies spécialement adaptées, destinées à des individus en cours de traitement avec des agents thérapeutiques ciblés sur l’IL-2R.
Latest bibliographic data on file with the International Bureau